What is MediciNova Inc?
, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 71.47M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.